<DOC>
	<DOCNO>NCT00541658</DOCNO>
	<brief_summary>The purpose trial study efficacy 35 mg delay release weekly dose regimen compare standard daily dose regimen risedronate 5 mg daily .</brief_summary>
	<brief_title>A Study 35 mg Delayed Release Formulation Risedronate Osteoporosis</brief_title>
	<detailed_description>The comparator arm risedronate study 35 mg delay release give weekly 5 mg immediate release give daily .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Female : 50 year age old &gt; 5 year since last menses natural surgical lumbar spine total hip BMD 2.5 SD young adult mean , lumbar spine total hip BMD 2.0 SD young adult female mean value also least one prevalent vertebral body fracture history uncontrolled hyperparathyroidism , hyperthyroidism , osteomalacia BMI &gt; 32 kg/m use medication within 3 month start study drug impact bone metabolism glucocorticoid , estrogen , calcitonin , calcitriol , bisphosphonates parathyroid hormone hypocalcemia hypercalcemia cause markedly abnormal clinical laboratory measurement assess clinically significant investigator</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>